Higher dose of enzyme treatment for Pompe disease
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests whether a higher dose of the enzyme medicine used for Pompe disease is safe and helpful. You may qualify if you already have Pompe disease and are currently receiving regular enzyme replacement therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of Pompe disease
- You are currently receiving enzyme replacement therapy (ERT) for Pompe disease
- You can attend regular clinic visits for your study participation
- You agree to sign the informed consent form
- You do not have an allergy to Myozyme (alglucosidase alpha)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if getting enzyme replacement therapy every 4 weeks instead of every 2 weeks is safe and effective for stable adults with late-onset Pompe disease. It may reduce the burden of frequent infusions.
This study tests the safety and effects of the enzyme replacement therapy avalglucosidase alfa (Nexviazyme) in children with infantile-onset Pompe disease. It is for children who have had Pompe symptoms since infancy and heart problems at diagnosis.
This trial is a registry, meaning it collects health information from people with confirmed Pompe disease. It may help researchers better understand the disease and improve future treatments.
This trial tests how well a new enzyme treatment (cipaglucosidase alfa with miglustat) works and how safe it is in children and babies with infant-onset Pompe disease. It may help by improving muscle function after earlier treatment or, for some babies, starting treatment when no prior enzyme therapy has been given.
This early-stage trial tests a new gene therapy for adults with late-onset Pompe disease who have already tried enzyme replacement therapy (ERT). The goal is to see if the gene therapy is safe and can help improve muscle strength and breathing.
This study tests an experimental drug (S-606001) for people with late-onset Pompe disease. It aims to see if the drug can improve breathing and walking ability. You cannot have had enzyme replacement therapy for at least 3 months before joining.
Hear when a new Glycogen Storage Disease Type II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.